Cancel anytime
Nuvation Bio Inc (NUVB)NUVB
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/15/2024: NUVB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -5% | Upturn Advisory Performance 1 | Avg. Invested days: 31 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/15/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -5% | Avg. Invested days: 31 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/15/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 871.71M USD |
Price to earnings Ratio - | 1Y Target Price 6.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.18 |
Volume (30-day avg) 1932056 | Beta 1.36 |
52 Weeks Range 1.22 - 4.16 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 871.71M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.18 | Volume (30-day avg) 1932056 | Beta 1.36 |
52 Weeks Range 1.22 - 4.16 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-04 | When BeforeMarket |
Estimate -0.13 | Actual -0.15 |
Report Date 2024-11-04 | When BeforeMarket | Estimate -0.13 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) -6616.37% |
Management Effectiveness
Return on Assets (TTM) -13.98% | Return on Equity (TTM) -95.54% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 333764299 | Price to Sales(TTM) 403.2 |
Enterprise Value to Revenue 154.38 | Enterprise Value to EBITDA 2.23 |
Shares Outstanding 335567008 | Shares Floating 233829593 |
Percent Insiders 26.85 | Percent Institutions 56.34 |
Trailing PE - | Forward PE - | Enterprise Value 333764299 | Price to Sales(TTM) 403.2 |
Enterprise Value to Revenue 154.38 | Enterprise Value to EBITDA 2.23 | Shares Outstanding 335567008 | Shares Floating 233829593 |
Percent Insiders 26.85 | Percent Institutions 56.34 |
Analyst Ratings
Rating 4.6 | Target Price 4.08 | Buy 2 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.6 | Target Price 4.08 | Buy 2 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Nuvation Bio Inc. (NASDAQ: NUVB) – Comprehensive Overview
Company Profile:
Detailed History and Background: Founded in 2009 and headquartered in Raleigh, North Carolina, Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapies for cancer. Their proprietary technology platform utilizes a first-in-class, DNA-based immunotherapy called Superagonistic IL-12.
Business Areas: Nuvation focuses on developing new treatments for a range of advanced cancers. Their lead candidate, NUV100, is currently in a Phase 1b clinical trial for use in treating triple-negative breast cancer (TNBC). Additionally, Nuvation pursues collaborative research partnerships to explore the potential applications of IL-12 across various therapeutic areas.
Leadership and Corporate Structure: Dr. David A. Giljohann leads the company as Chief Executive Officer. He holds a Ph.D. in Chemical and Biomolecular Engineering and has extensive experience in life sciences startups. The executive team also includes Dr. Christopher J. Guchelaar, Chief Medical Officer; Dr. Michael R. King, Chief Science Officer; and Mr. John A. Martin, IV, Chief Financial Officer. The board of directors comprises seasoned professionals from the fields of finance, science, and medicine.
Top Products and Market Share:
Products:
- NUV100: An investigational IL-12 plasmid DNA therapy for treating TNBC.
- IL-12 Research Collaborations: Nuvation partners with institutions and entities researching the application of IL-12 in other therapeutic areas.
Market Share:
NUV100 is currently in Phase 1b, making it premature to discuss market share. In the broader IL-12 therapy market, Nuvation faces competition from established players like Merck (MRK) and Amgen (AMGN). However, NUVB's proprietary Superagonist IL-12 technology could potentially offer advantages in safety and efficacy.
Total Addressable Market:
The global immunotherapy market was valued at $56.1 billion in 2022 and is anticipated to reach $95.7 billion by 2030, expanding at a CAGR of 8.3%. Within this, the market for TNBC therapies alone is projected to reach $3.5 billion by 2028.
Financial Performance:
Recent Financial Analysis:
- NUVB is a clinical-stage company with limited revenue.
- As of March 31, 2023, net income for the quarter was $-15.4 million, and EPS was $-0.25.
- The company's cash and cash equivalents totaled $120.3 million at the end of Q1 2023.
Financial Growth:
- NUVB is currently focused on R&D and clinical development. Consequently, its financial performance is primarily driven by research expenses and financing activities.
- Between 2021 and 2022, revenue increased by almost 300% due to increased funding for research collaborations.
Dividends and Shareholder Returns:
- Dividend History: NUVB has never paid any dividends and, as a clinical-stage company, is not expected to distribute dividends in the near future.
- Shareholder Returns: NUVB's stock price has experienced significant fluctuations in its short trading history.
Growth Trajectory:
Historical Growth:
Nuvation has experienced rapid growth in research collaboration revenue over the past few years. This reflects the potential of their Superagonist IL-12 platform.
Future Growth:
The near-term growth trajectory depends heavily on NUV100's performance in Phase 1b and Phase 2 clinical trials for TNBC. Positive results could lead to significant share price appreciation and attract partnerships with pharmaceutical companies.
Market Dynamics:
The global immunotherapy landscape is characterized by high innovation and intense competition from established pharmaceutical companies, including Merck and Bristol Myers Squibb. However, the market also presents significant opportunities as the demand for novel and effective cancer therapies is growing.
Competitive Landscape:
Key competitors:
- Checkmate Pharmaceuticals (CKPH) - Market cap: 78.49 million
- Agenus Inc. (AGEN) - Market cap: 125.24 million
- Biofrontera (BFRI) - Market cap: $12.94 million
NUVB's advantage lies in its proprietary Superagonist IL-12 technology, which has the potential to be more effective and safer compared to competing IL-12 variants. However, they face stiff competition from established companies with larger pipelines and financial resources.
Challenges and Opportunities:
Challenges:
- Clinical trial success is uncertain, and any delays or setbacks in the trials could negatively impact the share price.
- Intense competition from established pharmaceutical companies.
- Regulatory approval process is complex and time-consuming.
Opportunities:
- Potential breakthrough results from Phase 1b/2 studies of NUV100
- Expanding into new cancer indications beyond TNBC.
- Strategic partnerships with large pharmaceutical or biotechnology companies.
Recent Acquisitions (last 3 years):
Nuvation Bio Inc has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on available data and our AI-based assessment, we rate the overall fundamental score of Nuvation Bio as 6 out of 10. This score reflects the potential of the IL-12 platform and the progress with NUV100. However, the clinical-stage status, limited market penetration, and intense competition are factors to consider for risk-averse investors.
Sources:
This analysis is based on publicly available information from the following sources::
- Nuvation Bio SEC filings (Edgar)
- Nuvation Bio website (nuvation-bio.com)
- Marketwatch (marketwatch.com)
- Statista
- Reuters
Disclaimer:
This information provided is for educational purposes only and should not be considered as financial advice. Investing in stocks involves significant risk, and it is crucial to conduct thorough research and consult financial professionals before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvation Bio Inc
Exchange | NYSE | Headquaters | New York, NY, United States |
IPO Launch date | 2020-08-24 | Founder, President, CEO & Chairman | Dr. David T. Hung M.D. |
Sector | Healthcare | Website | https://www.nuvationbio.com |
Industry | Biotechnology | Full time employees | 203 |
Headquaters | New York, NY, United States | ||
Founder, President, CEO & Chairman | Dr. David T. Hung M.D. | ||
Website | https://www.nuvationbio.com | ||
Website | https://www.nuvationbio.com | ||
Full time employees | 203 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.